X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
chemotherapy (21) 21
oncology (19) 19
cancer (17) 17
index medicus (14) 14
aged (12) 12
humans (12) 12
patients (12) 12
male (11) 11
metastasis (11) 11
antimitotic agents (10) 10
antineoplastic agents (10) 10
care and treatment (10) 10
female (10) 10
oxaliplatin (10) 10
bevacizumab (9) 9
colorectal cancer (9) 9
gastric cancer (9) 9
cancer research (8) 8
medicine & public health (8) 8
gastroenterology and hepatology (7) 7
middle aged (7) 7
research (7) 7
stomach cancer (7) 7
trial (7) 7
adult (6) 6
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
cancer therapies (6) 6
cisplatin (6) 6
oncology, experimental (6) 6
original article (6) 6
surgery (6) 6
tumors (6) 6
case report (5) 5
neutropenia (5) 5
original (5) 5
s-1 (5) 5
survival (5) 5
toxicity (5) 5
treatment outcome (5) 5
1st-line treatment (4) 4
aged, 80 and over (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (4) 4
cancer patients (4) 4
capecitabine (4) 4
carcinoma, squamous cell - pathology (4) 4
colorectal carcinoma (4) 4
combination (4) 4
fluorouracil (4) 4
fluorouracil - administration & dosage (4) 4
folfoxiri (4) 4
follow-up studies (4) 4
gastroenterology & hepatology (4) 4
head (4) 4
irinotecan (4) 4
metastases (4) 4
neoplasms. tumors. oncology. including cancer and carcinogens (4) 4
pharmacology & pharmacy (4) 4
pharmacology/toxicology (4) 4
retrospective studies (4) 4
surgical oncology (4) 4
therapy (4) 4
5-fluorouracil (3) 3
adenocarcinoma (3) 3
analysis (3) 3
carcinoma, squamous cell - therapy (3) 3
cetuximab (3) 3
cisplatin - administration & dosage (3) 3
clinical trials (3) 3
diarrhea (3) 3
disease control (3) 3
drug administration schedule (3) 3
erbb-2 protein (3) 3
esophagus (3) 3
hepatitis (3) 3
leucovorin (3) 3
maximum tolerated dose (3) 3
medical research (3) 3
medicine, experimental (3) 3
metastatic colorectal cancer (3) 3
pharyngeal neoplasms - pathology (3) 3
prognosis (3) 3
radiotherapy (3) 3
research paper (3) 3
stomach neoplasms - drug therapy (3) 3
survival analysis (3) 3
trastuzumab (3) 3
1st-line therapy (2) 2
adjuvant chemotherapy (2) 2
adjuvant treatment (2) 2
alk mutation (2) 2
anemia (2) 2
anorexia (2) 2
antimetabolites, antineoplastic - administration & dosage (2) 2
antimetabolites, antineoplastic - adverse effects (2) 2
asian continental ancestry group (2) 2
biliary tract cancer (2) 2
biopsy (2) 2
breast cancer (2) 2
capecitabine - administration & dosage (2) 2
capecitabine - adverse effects (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. 6552 - 6552
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2017, Volume 35, Issue 15_suppl, pp. e18263 - e18263
Journal Article
Nihon rinsho. Japanese journal of clinical medicine, ISSN 0047-1852, 05/2015, Volume 73, Issue 5, pp. 866 - 874
Journal Article
Nihon rinsho. Japanese journal of clinical medicine, ISSN 0047-1852, 05/2015, Volume 73, Issue 5, p. 866
The purpose of a therapeutic clinical trial is to determine the value of a treatment. The main objectives of phase I trials have been to determine a dose that... 
Neoplasms - therapy | Humans | Clinical Trials as Topic | Molecular Targeted Therapy
Journal Article
INTERNAL MEDICINE, ISSN 0918-2918, 2019, Volume 58, Issue 7, pp. 1029 - 1032
Inflammatory myofibroblastic tumor (IMT), a rare sarcoma, is primarily treated via resection of the mass. However, in cases of recurrence or unresectable... 
MEDICINE, GENERAL & INTERNAL | crizotinib | ALK mutation | EXPRESSION | inflammatory myofibroblastic tumor | Inhibitors | Sarcoma | Lung cancer | Case reports | Inflammation | Mutation | Kinases | Lymphoma | Protein-tyrosine kinase | Tumors | Case Report
Journal Article
Case Reports in Oncology, ISSN 1662-6575, 03/2018, Volume 11, Issue 1, pp. 143 - 150
Following the ATTRACTION-2 study, nivolumab was approved for advanced gastric cancer in Japan. However, pseudoprogression and hyperprogressive disease have... 
Case Report | Hyperprogressive disease | Immune checkpoint inhibitors | Pseudoprogression | Radiotherapy | Gastric cancer | Nivolumab | Lymphatic system | Laboratories | Lung cancer | Melanoma | Cytotoxicity | Metastasis | Radiation therapy | Patients | Cancer therapies | Stomach cancer | Esophagus | Chemotherapy | Immunology | Immunotherapy | Dysphagia | Growth factors | Tumors
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 11/2018, Volume 82, Issue 5, pp. 839 - 845
Optimal salvage chemotherapy for patients with treated advanced/metastatic gastric cancer (AGC) is unknown. Irinotecan is commonly used in Japan. Ramucirumab,... 
Medicine & Public Health | Oncology | Cancer Research | Salvage therapy/MT | Vascular endothelial growth factor receptor/AI | Pharmacology/Toxicology | Stomach neoplasms/DT | Antagonists and inhibitors: topoisomerase I inhibitors | PLUS CISPLATIN | MULTICENTER | PLACEBO | ADENOCARCINOMA | OXALIPLATIN | COMBINATION | TRIAL | POLYMORPHISMS | ONCOLOGY | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | 1ST-LINE THERAPY | Bridged-Ring Compounds - therapeutic use | Irinotecan - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Platinum - therapeutic use | Drug Administration Schedule | Humans | Antibodies, Monoclonal - adverse effects | Kaplan-Meier Estimate | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Platinum - administration & dosage | Stomach Neoplasms - drug therapy | Irinotecan - adverse effects | Taxoids - administration & dosage | Taxoids - therapeutic use | Maximum Tolerated Dose | Antibodies, Monoclonal - administration & dosage | Survival Analysis | Female | Aged | Bridged-Ring Compounds - administration & dosage | Salvage Therapy - methods | Antimitotic agents | Chemotherapy | Endothelial growth factors | Oncology, Experimental | Monoclonal antibodies | Research | Antineoplastic agents | Stomach cancer | Cancer | Hypertension | Anemia | Toxicity | Immunoglobulin G | Taxane | Disease control | Patients | Metastases | Irinotecan | Salvage | Platinum | Vascular endothelial growth factor | Gastric cancer | Neutropenia | Vascular endothelial growth factor receptor | Original | Stomach neoplasms | Salvage therapy
Journal Article
International Journal of Clinical Oncology, ISSN 1341-9625, 10/2017, Volume 22, Issue 5, pp. 913 - 920
This study was designed to evaluate the efficacy and toxicity of XELIRI plus bevacizumab for the treatment of Japanese patients with unresectable or recurrent... 
Irinotecan | First-line chemotherapy | Medicine & Public Health | Capecitabine | Multicenter single-arm open-label prospective clinical trial | Oncology | Cancer Research | Surgical Oncology | Metastatic colorectal cancer | Bevacizumab | CONTROLLED-TRIAL | LEUCOVORIN | OXALIPLATIN | TOXICITY | FLUOROURACIL | COMBINATION | CHEMOTHERAPY | ORAL CAPECITABINE | ONCOLOGY | RANDOMIZED PHASE-II | Capecitabine - administration & dosage | Colorectal Neoplasms - surgery | Prospective Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Recurrence, Local - drug therapy | Male | Diarrhea - chemically induced | Fluorouracil - administration & dosage | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Camptothecin - administration & dosage | Female | Neutropenia - chemically induced | Camptothecin - analogs & derivatives | Glucuronosyltransferase | Bevacizumab - administration & dosage | Treatment Outcome | Disease-Free Survival | Asian Continental Ancestry Group | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Anorexia - chemically induced | Aged | Colorectal Neoplasms - pathology | Antimitotic agents | Medical research | Care and treatment | Relapse | Chemotherapy | Colorectal cancer | Medicine, Experimental | Metastasis | Antineoplastic agents | Diseases | Cancer | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2018, Volume 36, Issue 4_suppl, pp. 155 - 155
Journal Article
Case Reports in Oncology, ISSN 1662-6575, 01/2017, Volume 10, Issue 1, pp. 81 - 85
It has been reported that many patients with lung metastasis of colorectal cancer (CRC) underwent chemotherapy with fluorouracil, folinic acid, oxaliplatin,... 
Chemotherapy | Bevacizumab+XELIRI | Lung metastasis | Colorectal cancer | Medical imaging | Metastasis | Patients | Cancer therapies | Tumors
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2017, Volume 28, Issue suppl_9
Journal Article
Annals of Oncology, ISSN 0923-7534, 06/2017, Volume 28, Issue suppl_3
Journal Article
Case Reports in Oncology, ISSN 1662-6575, 10/2017, Volume 10, Issue 3, pp. 885 - 889
Oxaliplatin-based chemotherapy is widely used to treat advanced cancer. Oxaliplatin-induced hyperammonemic encephalopathy is rarely reported. Here, we report a... 
Case Report | Hyperammonemic encephalopathy | GEMOX | Urea cycle | Oxaliplatin | Pancreatic cancer | Hyperammonemia | Antigens | Enzymes | Consciousness | Laboratories | Liver | Clinical trials | Family medical history | Metastasis | Patients | Cancer therapies | Blood | Hepatitis | Chemotherapy | Tomography | Constipation
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 7/2016, Volume 78, Issue 1, pp. 91 - 99
Journal Article
Oncotarget, ISSN 1949-2553, 10/2018, Volume 9, Issue 77, pp. 34520 - 34527
The neutrophil-to-lymphocyte ratio (NLR) is effective as a predictive factor for lung cancer treated with nivolumab. The objective of this study was to... 
Predictive factors | Neutrophil-to-lymphocyte ratio | Advanced gastric cancer | Nivolumab | Prognostic factors
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.